"We’re going to tariff our pharmaceuticals, and once we do that, they’re going to come rushing back into our country because ...

The Dow Jones Industrial Average (DJINDICES: ^DJI) fell sharply after the U.S. released a new tariff program. Does that open ...

Merck is in hot water after a class action lawsuit alleged securities fraud over its Gardasil revenue forecasts in China. The lawsuit claims Merck misled investors about its ability to achieve $11 ...

We recently published a list of 10 Defensive Stocks Billionaire Ken Fisher is Betting On. In this article, we are going to ...

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

Analysts have mixed feelings about Merck & Co., Inc., assigning it a “Moderate Buy” with an average price target of $117.12.

In a recent appearance on CNBC’s Squawk on the Street, Jim Cramer shared what the Trump administration could do to stop the ...

In a report released today, Tim Anderson from Bank of America Securities maintained a Buy rating on Merck & Company (MRK – Research ...

Janux Therapeutics' lead drug, JANX007, shows promising prostate cancer results with no serious side effects. Find out why ...

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Merck & Co., Inc. ("Merck" or the "Company") and reminds investors of the April 14, 2025 ...

Research analysts at Zacks Research lowered their Q4 2026 EPS estimates for shares of Merck & Co., Inc. in a report released ...